{"id":"cdmard","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"},{"rate":"null","effect":"Liver enzyme elevations"},{"rate":"null","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition leads to a decrease in the production of autoantibodies, which are thought to contribute to the development of autoimmune diseases. By reducing the levels of these autoantibodies, cDMARDs can help to slow down disease progression and reduce symptoms. However, the exact mechanisms by which cDMARDs exert their therapeutic effects are not fully understood.","oneSentence":"cDMARDs work by inhibiting the enzyme peptidyl arginine deiminase, which is involved in the production of autoantibodies.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:08.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT07436494","phase":"","title":"Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs","status":"COMPLETED","sponsor":"Bursa City Hospital","startDate":"2020-10-15","conditions":"COVID-19, Anxiety, Rheumatic Diseases","enrollment":200},{"nctId":"NCT05717179","phase":"NA","title":"Ultrasound to Guide Treatment Decisions in Patients With Rheumatoid Arthritis According to a T2T Approach","status":"RECRUITING","sponsor":"Italian Society for Rheumatology","startDate":"2023-02-22","conditions":"Arthritis, Rheumatoid, Ultrasound, Treat to Target","enrollment":158},{"nctId":"NCT04871191","phase":"PHASE3","title":"Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03","conditions":"Granulomatosis with Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis","enrollment":42},{"nctId":"NCT06558305","phase":"","title":"IL-6, IL-12, IL-15 and IL-23 Expression Levels in Rheumatoid Arthritis Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-09","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT01885078","phase":"PHASE3","title":"An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06-27","conditions":"Rheumatoid Arthritis","enrollment":2877},{"nctId":"NCT03264703","phase":"","title":"Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2017-09-11","conditions":"Arthritis, Rheumatoid","enrollment":212},{"nctId":"NCT01721044","phase":"PHASE3","title":"A Moderate to Severe Rheumatoid Arthritis Study","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-01","conditions":"Rheumatoid Arthritis","enrollment":527},{"nctId":"NCT01721057","phase":"PHASE3","title":"A Study in Moderate to Severe Rheumatoid Arthritis Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":684},{"nctId":"NCT02648035","phase":"","title":"EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-09-22","conditions":"Rheumatoid Arthritis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":82,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"cDMARD","genericName":"cDMARD","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"cDMARDs work by inhibiting the enzyme peptidyl arginine deiminase, which is involved in the production of autoantibodies. Used for Rheumatoid arthritis, Psoriatic arthritis, Juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}